Cancer immunotherapy, especially using T cells, is showing a lot of promise in treating blood cancers. Bioengineered T cells, ...

Glioblastoma (GBM), the most aggressive primary brain tumor, continues to portend a poor prognosis with median survival under ...

Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and ...

A major European clinical research event in oncology gives a boost to antibody–drug conjugates, treatments that work like a Trojan horse, delivering chemotherapy to the interior of malignant cells ...

New triple therapy reprograms cancer cell death, helping the immune system destroy tumors. The goal of immunotherapy is to activate a patient’s own immune system to target and destroy tumor cells. In ...

The global car t-cell therapy market size is predicted to increase from USD 7.64 billion in 2025 and is anticipated to be ...

Liberate Bio’s CAR-M cell therapy almost completely depleted B-cells in a nonhuman primate study, the company said.

Molecular analysis identified ABC and GCB subtypes, with the ABC subtype benefiting more from the new regimen. The ...

Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.

When it comes to treating disease, one promising avenue is addressing the presence of senescent cells. These cells—also known ...